Abstract:Objective: This study aimed to investigate epidemiological characteristics, clinical manifestations, and long-term outcomes of patients with autoimmune encephalitis (AE) in the east of China. Methods: From January 2015 to December 2019, 226 potential AE patients were recruited from five clinical centers, and a total of 185 patients who met the diagnostic criteria were included in the study. We retrospectively reviewed clinical features, auxiliary examinations, details of treatments, and outcomes of AE, and identified risk factors of poor prognosis. Modified Rankin Scale scores were used to evaluate neurological function, and scores of 3–6 indicated a poor-prognosis. Results: Patients with five main subtypes of AE were enrolled in the study, as follows: anti-NMDAR (79), anti-LGI1 (55), anti-CASPR2 (30), anti-GABABR (16), and anti-AMPAR (5). Among 185 patients, 58.38% (108/185) were male and 41.62% (77/185) were female. The median age at disease onset was 41 years (interquartile range, 17–62). The most common clinical manifestations of AE were seizures (146, 78.92%) and memory deficit (123, 66.49%). A total of 95 (51.35%) patients had abnormal brain magnetic resonance imaging results. Electroencephalographic findings were abnormal in 131 (70.81%) patients, and 168 (90.81%) and 26 (14.05%) patients were treated with first- and second-line immunotherapies, respectively. All surviving patients were followed-up for at least 1 year (range 12–36 months). Good clinical outcomes were achieved in 117 (63.24%), while 68 (36.76%) patients had a poor prognosis. Further, 33 (17.84%) patients relapsed and 10 (5.41%) died within 1 year post-discharge. Older patients tended to have a poorer prognosis, and the occurrence of mental behavioral disorders, movement disorders, disturbance of consciousness, central hypoventilation, and tumors were overrepresented in the poor-prognosis group. Conclusions: AE is a treatable disease, and most patients have a good prognosis. There are differences in the clinical manifestations of patients with different AE subtypes. Some with AE will relapse, and long-term follow-up is of great significance for further research.

B-cell targeted therapies in autoimmune encephalitis: mechanisms, clinical applications, and therapeutic potential

Immunotherapy for Refractory Autoimmune Encephalitis

Navigating the diagnostic and therapeutic complexities of autoimmune encephalitis

Autoimmune Encephalitis: Insights Into Immune-Mediated Central Nervous System Injury

Treatment strategies for autoimmune encephalitis

Hello from the Other Side: How Autoantibodies Circumvent the Blood–Brain Barrier in Autoimmune Encephalitis

An Update on the Treatment of Pediatric Autoimmune Encephalitis

Impact of blood-brain barrier disruption on clinical features and treatment response in patients with newly diagnosed autoimmune encephalitis

First-line Immunotherapy of Neuronal Surface Antibody-Mediated Autoimmune Encephalitis: Assessment of Therapeutic Effectiveness and Cost-Efficiency

Treatment Approaches in Pediatric Relapsing Autoimmune Encephalitis

Immune therapy in autoimmune encephalitis: a systematic review

Autoimmune encephalitis with coexisting antibodies to GABABR, GAD65, SOX1 and Ma2

Immunotherapy and prognosis of autoimmune encephalitis

Pediatric Autoimmune Encephalitis and Its Relationship With Infection

[Main Syndrome and Antibody Effects of Autoimmune Encephalitis Caused by Antineuronal Surface Antibodies: An Update]

Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study

Emerging Biomarkers for the Early Detection of Autoimmune Encephalitis: A Narrative Review

Role of Plant-Derived Natural Compounds in Experimental Autoimmune Encephalomyelitis: A Review of the Treatment Potential and Development Strategy

Clinical features and immunotherapy outcomes in antibody-negative autoimmune encephalitis: a retrospective case-control study

Treatment Options in Refractory Autoimmune Encephalitis

Predicting the future of autoimmune encephalitides